The Anorexigenic Fatty Acid Synthase Inhibitor, C75, Is a Nonspecific Neuronal Activator

Endocrinology

Volumn 145, Issue 1, 2004, Pages 184-193

  Takahashi, Kanji A ^a   Smart, James L ^a   Liu, Hongyan ^b   Cone, Roger D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; ANOREXIGENIC AGENT; C 75; CERULENIN; FATTY ACID SYNTHASE; GREEN FLUORESCENT PROTEIN; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARCUATE NUCLEUS; ARTICLE; BODY WEIGHT; CELL TYPE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEEDING; FEMALE; FOOD INTAKE; HYPOTHALAMUS; KNOCKOUT MOUSE; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PURKINJE CELL; WEIGHT REDUCTION; WILD TYPE;

4-BUTYROLACTONE; ACTION POTENTIALS; ANIMALS; ARCUATE NUCLEUS; EATING; FATTY ACID SYNTHETASE COMPLEX; FECES; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; NEUROPEPTIDE Y; PATCH-CLAMP TECHNIQUES; PRO-OPIOMELANOCORTIN; PURKINJE CELLS; WEIGHT LOSS;

EID: 0347719519     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0337     Document Type: Article

References (78)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL 2002 Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727
2. Wolf AM, Colditz GA 1998 Current estimates of the economic cost of obesity in the United States. Obese Res 6:97-106
3. Pi-Sunyer FX 1993 Medical hazards of obesity. Ann Intern Med 119:655-660
4. Mun EC, Blackburn GL, Matthews JB 2001 Current status of medical and surgical therapy for obesity. Gastroenterology 120:669-681
5. Rosenbaum M, Leibel RL 1998 The physiology of body weight regulation: relevance to the etiology of obesity in children. Pediatrics 101:525-539
6. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL 2002 Low-dose leptin administration reverses effects of sustained weight reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 87:2391-2394
7. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA 2000 Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97:3450-3454
8. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP 2000 Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2379-2381
9. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP 2002 C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA 99:9498-9502
10. Kumar MV, Shimokawa T, Nagy TR, Lane MD 2002 Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice. Proc Natl Acad Sci USA 99:1921-1925
11. Shimokawa T, Kumar MV, Lane MD 2002 Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc Natl Acad Sci USA 99:66-71
12. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ 2001 Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411:480-484
13. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F 1997 Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131-141
14. Butler AA, Marks DL, Fan W, Kuhn CM, Bartolome M, Cone RD 2001 Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci 4:605-611
15. Ruderman NB, Saha AK, Vavvas D, Witters LA 1999 Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 276:E1-E18
16. Stryer L 1995 Biochemistry. 4th ed. New York: W. H. Freeman and Company; 614-628
17. Brun T, Roche E, Assimacopoulos-Jeannet F, Corkey BE, Kim KH, Prentki M 1996 Evidence for an anaplerotic/malonyl-CoA pathway in pancreatic β-cell nutrient signaling. Diabetes 45:190-198
18. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD 1997 Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385:165-168
19. Brady LS, Smith MA, Gold PW, Herkenham M 1990 Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. Neuroendocrinology 52:441-447
20. Bergendahl M, Wiemann JN, Clifton DK, Huhtaniemi I, Steiner RA 1992 Short-term starvation decreases POMC mRNA but does not alter GnRH mRNA in the brain of adult male rats. Neuroendocrinology 56:913-920
21. Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, Burn P, Baskin DG 1997 Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46:2119-2123
22. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S 1998 Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393:72-76
23. Thornton JE, Cheung CC, Clifton DK, Steiner RA 1997 Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 138:5063-5066
24. Elias CF, Aschkenasi C, Lee C, Kelly J, Ahima RS, Bjorbaek C, Flier JS, Saper CB, Elmquist JK 1999 Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 23:775-786
25. Marks DL, Butler AA, Turner R, Brookhart G, Cone RD 2003 Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 144:1513-1523
26. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U 1999 Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5:1066-1070
27. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A 1998 Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19:155-157
28. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone RD 2000 A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-defident mouse. Endocrinology 141: 3518-3521
29. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van der Ploeg LH 2000 Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 26:97-102
30. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, O'Rahilly S 2000 Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106:271-279
31. Cone RD 2000 Haploinsufficiency of the melanocortin-4 receptor: part of a thrifty genotype? J Clin Invest 106:185-187
32. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P 2000 Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106:253-262
33. Chua Jr SC, Brown AW, Kim J, Hennessey KL, Leibel RL, Hirsch J 1991 Food deprivation and hypothalamic neuropeptide gene expression: effects of strain background and the diabetes mutation. Brain Res Mol Brain Res 11:291-299
34. Mizuno TM, Mobbs CV 1999 Hypothalamic agouti-related protein messenger ribonudeic acid is inhibited by leptin and stimulated by fasting. Endocrinology 140:814-817
35. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF 1986 Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7:1189-1192
36. Rossi M, Kim MS, Morgan DG, Small CJ, Edwards CM, Sunter D, Abusnana S, Goldstone AP, Russell SH, Stanley SA, Smith DM, Yagaloff K, Ghatei MA, Bloom SR 1998 A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of a-melanocyte stimulating hormone in vivo. Endocrinology 139:4428-4431
37. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD 1994 Agouti protein is an antagonist of the melanocyte-stirnulating-hormone receptor. Nature 371:799-802
38. Haskell-Luevano C, Chen P, Li C, Chang K, Smith MS, Cameron JL, Cone RD 1999 Characterization of the neuroanatomical distribution of agouti-related protein immunoreactivity in the rhesus monkey and the rat. Endocrinology 140:1408-1415
39. Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I, Akil H, Barsh GS, Watson SJ 1999 Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J Neurosci 19:RC26:1-7
40. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD 1999 Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24:155-163
41. Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL 2003 The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649-661
42. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR 2002 Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
43. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE, Cone RD, Elmquist JK 2002 Activation of central melanocortin pathways by fenfluramine. Science 297: 609-611
44. Deleted in proof
45. Pollok BA, Heim R 1999 Using GFP in FRET-based applications. Trends Cell Biol 9:57-60
46. Roberts WM, Almers W 1992 Patch voltage clamping with low-resistance seals: loose patch clamp. Methods Enzymol 207:155-176
47. De Souza J, Butler AA, Cone RD 2000 Disproportionate inhibition of feeding in A(y) mice by certain stressors: a cautionary note. Neuroendocrinology 72:126-132
48. Hausser M, Clark BA 1997 Tonic synaptic inhibition modulates neuronal output pattern and spatiotemporal synaptic integration. Neuron 19:665-678
49. Llinas R, Sugimori M 1980 Electrophysiological properties of in vitro Purkinje cell somata in mammalian cerebellar slices. J Physiol 305:171-195
50. Clegg DJ, Wortman MD, Benoit SC, McOsker CC, Seeley RJ 2002 Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. Diabetes 51:3196-3201
51. Wortman MD, Clegg DJ, D'Alessio D, Woods SC, Seeley RJ 2003 C75 inhibits food intake by increasing CNS glucose metabolism. Nat Med 9:483-485
52. Gao S, Lane MD 2003 Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci USA 100:5628-5633
53. Omura S 1981 Cerulenin. Methods Enzymol 72:520-532
54. Schlesinger MJ, Malfer C 1982 Cerulenin blocks fatty acid acylation of glycoproteins and inhibits vesicular stomatitis and Sindbis virus particle formation. J Biol Chem 257:9887-9890
55. Jochen AL, Hays J, Mick G 1995 Inhibitory effects of cerulenin on protein palmitoylation and insulin internalization in rat adipocytes. Biochim Biophys Acta 1259:65-72
56. Lawrence DS, Zilfou JT, Smith CD 1999 Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors. J Med Chem 42:4932-4941
57. Wall L, Meighen E 1989 Covalent reaction of cerulenin at the active site of acyl-CoA reductase of Photobacterium phosphoreum. Biochem Cell Biol 67: 163-167
58. Thupari JN, Pinn ML, Kuhajda FP 2001 Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285:217-223
59. Robinson RB, Siegelbaum SA 2003 Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 65:453-480
60. Do MT, Bean BP 2003 Subthreshold sodium currents and pacemaking of subthalamic neurons. Modulation by slow inactivation. Neuron 39:109-120
61. Womack M, Khodakhah K 2002 Active contribution of dendrites to the tonic and trimodal patterns of activity in cerebellar Purkinje neurons. J Neurosci 22:10603-10612
62. Womack MD, Khodakhah K 2002 Characterization of large conductance Ca2+-activated K+ channels in cerebellar Purkinje neurons. Eur J Neurosci 16:1214-1222
63. Womack MD, Khodakhah K 2003 Somatic and dendritic small-conductance calcium-activated potassium channels regulate the output of cerebellar purkinje neurons. J Neurosci 23:2600-2607
64. Falo Jr LD, Benacerraf B, Rothstein L, Rock KL 1987 Cerulenin is a potent inhibitor of antigen processing by antigen-presenting cells. J Immunol 139: 3918-3923
65. Ueno K 2000 Involvement of fatty acid synthase in axonal development in mouse embryos. Genes Cells 5:859-869
66. Hurley JH, Cahill AL, Currie KP, Fox AP 2000 The role of dynamic palmitoylation in Ca2+ channel inactivation. Proc Natl Acad Sci USA 97:9293-9298
67. Kim EK, Miller I, Landree LE, Borisy-Rudin FF, Brown P, Tihan T, Townsend CA, Witters LA, Moran TH, Kuhajda FP, Ronnett GV 2002 Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment. Am J Physiol Endocrinol Metab 283:E867-E879
68. Makimura H, Mizuno TM, Yang XJ, Silverstein J, Beasley J, Mobbs CV 2001 Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting. Diabetes 50:733-739
69. Yajima H, Komatsu M, Yamada S, Straub SG, Kaneko T, Sato Y, Yamauchi K, Hashizume K, Sharp GW, Aizawa T 2000 Cerulenin, an inhibitor of protein acylation, selectively attenuates nutrient stimulation of insulin release: a study in rat pancreatic islets. Diabetes 49:712-717
70. Yamada S, Komatsu M, Aizawa T, Sato Y, Yajima H, Yada T, Hashiguchi S, Yamauchi K, Hashizume K 2002 Time-dependent potenriation of the β-cell is a Ca2+-independent phenomenon. J Endocrinol 172:345-354
71. Oda T, Wu HC 1993 Cerulenin inhibits the cytotoxicity of ricin, modeccin, Pseudomonas toxin, and diphtheria toxin in brefeldin A-resistant cell lines. J Biol Chem 268:12596-12602
72. Straub SG, Yajima H, Komatsu M, Aizawa T, Sharp GW 2002 The effects of cerulenin, an inhibitor of protein acylation, on the two phases of glucose-stimulated insulin secretion. Diabetes 51(Suppl 1):S91-S95
73. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR 1994 Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379-6383
74. Semrad CE, Chang EB 2000 Approach to the patient with diarrhea. In: Humes HD, ed. Kelley's textbook of internal medicine. Philadelphia: Lippincott Williams, Wilkins; 738-755
75. Miller AD, Leslie RA 1994 The area postrema and vomiting. Front Neuroendocrinol 15:301-320
76. Schwartz GJ, Moran TH 2002 Leptin and neuropeptide y have opposing modulatory effects on nucleus of the solitary tract neurophysiological responses to gastric loads: implications for the control of food intake. Endocrinology 143:3779-3784
77. Schwartz GJ 2000 The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 16:866-873
78. Gross PM, Wall KM, Pang JJ, Shaver SW, Wainman DS 1990 Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius. Am J Physiol 259:R1131-R1138